RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Fujian Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07142122, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma (papillary, tubular, mucinous, poorly cohesive including signet-ring cell carcinoma, or mixed type).

    Inclusion criterion 2

  3. Clinical stage cT1bN0M0 without lymph node metastasis.

    Inclusion criterion 4

  4. ECOG performance status 0-1.

    Inclusion criterion 8

  5. Other malignancies within 5 years.

    Exclusion criterion 2

  6. Pregnancy or breastfeeding.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07142122, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-75 years.
  • Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma (papillary, tubular, mucinous, poorly cohesive including signet-ring cell carcinoma, or mixed type).
  • Primary tumor located in the upper third of the stomach, or esophagogastric junction cancer with tumor size ≤4 cm.
  • Clinical stage cT1bN0M0 without lymph node metastasis.
  • BMI <30 kg/m².
  • No history of upper abdominal surgery (except laparoscopic cholecystectomy).
  • No prior chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
  • ECOG performance status 0-1.
  • ASA class I-III.
  • Adequate organ function.
  • Signed informed consent.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Other malignancies within 5 years.
  • Active infection requiring systemic therapy or fever ≥38°C preoperatively.
  • Severe psychiatric illness.
  • Severe respiratory disease.
  • Severe hepatic or renal dysfunction.
  • Unstable angina or myocardial infarction within 6 months.
  • Stroke or intracranial hemorrhage within 6 months.
  • Long-term systemic glucocorticoid therapy within 1 month (local use excluded).
  • Complications of gastric cancer (bleeding, perforation, obstruction).
  • Participation in another clinical study within 6 months.

Exclusion During Study (Removal Criteria):

R0 resection not achieved, change of procedure to total gastrectomy or PPG, combined surgery for other diseases, severe perioperative complications, emergency surgery required, patient withdrawal of consent, or protocol violation.

Quoted from ClinicalTrials.gov, NCT07142122, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07142122, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07142122